Prime Medicine (PRME) Institutional Ownership

70.37% of Prime Medicine's stock is owned by institutional investors. Learn more on PRME's institutional investor holdings.

Of the 152 institutional investors that purchased Prime Medicine's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Farallon Capital Management LLC ($4.75M), State Street Corp ($3.84M), ARK Investment Management LLC ($3.29M), Balyasny Asset Management L.P. ($3.09M), Woodline Partners LP ($3.00M), RA Capital Management L.P. ($3M), and UBS Group AG ($2.25M).

Institutional investors have bought a total of 47,366,533 shares in the last 24 months. This purchase volume represents approximately $214.18M in transactions.

Of the 35 institutional investors that sold Prime Medicine's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: T. Rowe Price Investment Management Inc. ($11.34M), Farallon Capital Management LLC ($3.51M), Sumitomo Mitsui Trust Group Inc. ($2.02M), Millennium Management LLC ($1.37M), Nikko Asset Management Americas Inc. ($1.34M), ARK Investment Management LLC ($881.83K), and Invesco Ltd. ($705.30K).

Institutional investors have sold a total of 23,880,724 shares in the last 24 months. This volume of shares sold represents approximately $71.70M in transactions.